# Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

> **NCT07148128** · PHASE1,PHASE2 · RECRUITING · sponsor: **Auricula Biosciences Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
- Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
- Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
- Advanced Solid Tumors
- Advanced or Metastatic KRAS-mutant Tumor

## Interventions

- **DRUG:** WEF-001

## Key facts

- **NCT ID:** NCT07148128
- **Lead sponsor:** Auricula Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148128, "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07148128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*